This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read scPharmaceuticals’s 8K filing here.
About scPharmaceuticals
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.
Featured Stories
- Five stocks we like better than scPharmaceuticals
- Trading Halts Explained
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- With Risk Tolerance, One Size Does Not Fit All
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Comparing and Trading High PE Ratio Stocks
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
